EMAIL THIS PAGE TO A FRIEND

Turkiye parazitolojii dergisi

[Therapeutic efficacy of buparvaquone (buparvon) in cattle with theileriosis].


PMID 19156603

Abstract

The aim of this study was to examine the efficacy of buparvaquone (Buparvon, ALKE, Istanbul) in the treatment of theileriosis in cattle. The causative agent T. annulata causes direct and indirect gross economical loss in Turkey. Theileriosis was microscopically diagnosed by determining the presence of piroplasms in erythrocytes in thin blood smears stained with Giemsa stain. Buparvaquone was administered intramuscularly to the cattle with theileriosis using a single dose of 2.5 mg/kg. Clinical and laboratory examinations in cattle with theileriosis were carried out before and on the first, third and seventh days after treatment. As a result, it was concluded that a single deep intramuscular dose of 2.5 mg/kg buparvaquone was effective in the treatment of cattle which are naturally infected with T. annulata. However, further studies are needed using control groups of the same breed and age including suitable numbers of naturally infected and experimentally infected cattle.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

32154
Buparvaquone, VETRANAL, analytical standard
C21H26O3